Skip to main content
. 2018 Jun;9(3):478–486. doi: 10.21037/jgo.2018.03.13

Figure 1.

Figure 1

Progression-free survival (PFS) of patients with high and low PNLR. (A) Kaplan-Meier PFS curves in months from the diagnosis of metastatic adenocarcinoma of patients with PNLR below and above the cut-off of 2,000. Log rank test P<0.001; (B) forest plot results of the logistic regression analysis using the Cox-proportional hazards model of PFS as the outcome variable and PNLR, age, CEA (≤5 µg/L), LDH (>210 U/L), metastasectomy and ECOG >1 at presentation of metastatic disease as the predictor variables. PNLR, platelet-neutrophil to lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; CEA, carcinoembryonic antigen; LDH, lactate dehydrogenase; HR, hazard ratio.